Zobrazeno 1 - 10
of 244
pro vyhledávání: '"Martin F. Fromm"'
Autor:
Kim-Viktoria Bolik, Jan Hellmann, Simone Maschauer, Eduard Neu, Jürgen Einsiedel, Patrick Riss, Nora Vogg, Jörg König, Martin F. Fromm, Harald Hübner, Peter Gmeiner, Olaf Prante
Publikováno v:
EJNMMI Research, Vol 14, Iss 1, Pp 1-16 (2024)
Abstract Background The orexin receptor (OXR) plays a role in drug addiction and is aberrantly expressed in colorectal tumors. Subtype-selective OXR PET ligands suitable for in vivo use have not yet been reported. This work reports the development of
Externí odkaz:
https://doaj.org/article/7220bee43e0941a9b4e53a8f1aa38dba
Autor:
Anne T. Nies, Jörg König, Patrick Leuthold, Katja Damme, Stefan Winter, Mathias Haag, Satohiro Masuda, Stephan Kruck, Hannelore Daniel, Britta Spanier, Martin F. Fromm, Jens Bedke, Ken-ichi Inui, Matthias Schwab, Elke Schaeffeler
Publikováno v:
Pharmacological Research, Vol 196, Iss , Pp 106941- (2023)
Solute carrier (SLC) transport proteins are fundamental for the translocation of endogenous compounds and drugs across membranes, thus playing a critical role in disease susceptibility and drug response. Because only a limited number of transporter s
Externí odkaz:
https://doaj.org/article/a586ce376abb4a7f9f1e1058fa095696
Autor:
Arne Gessner, Anna Gemeinhardt, Agnes Bosch, Dennis Kannenkeril, Christian Staerk, Andreas Mayr, Martin F. Fromm, Roland E. Schmieder, Renke Maas
Publikováno v:
Cardiovascular Diabetology, Vol 21, Iss 1, Pp 1-11 (2022)
Abstract Background In patients with type 2 diabetes (T2D) sodium-glucose cotransporter 2 (SGLT-2) inhibitors improve glycaemic control as well as cardiovascular and renal outcomes. Their effects on l-arginine (Arg) related risk markers asymmetric an
Externí odkaz:
https://doaj.org/article/84d0ad9359a24a469e3fdccbc5dcb7ea
Publikováno v:
Healthcare, Vol 11, Iss 11, p 1640 (2023)
Generating evidence for the efficacy of an intervention is not sufficient to guarantee its implementation in real-world settings. The randomized AMBORA trial (Medication Safety with Oral Antitumor Therapy) demonstrated that an intensified clinical ph
Externí odkaz:
https://doaj.org/article/ea67e34193274ea285ca8eb1cccfc4ff
Publikováno v:
Pharmaceutics, Vol 15, Iss 3, p 738 (2023)
Due to alternative splicing, the SLCO1B3 gene encodes two protein variants; the hepatic uptake transporter liver-type OATP1B3 (Lt-OATP1B3) and the cancer-type OATP1B3 (Ct-OATP1B3) expressed in several cancerous tissues. There is limited information a
Externí odkaz:
https://doaj.org/article/c05c60f201474b81b3d9b9b6272fb02d
Autor:
Tom Zimmermann, Sebastian Staebler, R. Verena Taudte, Sumeyya Ünüvar, Sabine Grösch, Stephanie Arndt, Sigrid Karrer, Martin F. Fromm, Anja-Katrin Bosserhoff
Publikováno v:
Cancers, Vol 15, Iss 4, p 1064 (2023)
Cold atmospheric plasma (CAP) describes a partially ionized gas carrying large amounts of reactive oxygen (ROS) and nitrogen species (RNS). Numerous studies reported strong antitumor activity of CAP, thus rendering it a promising approach for tumor t
Externí odkaz:
https://doaj.org/article/a277fe9fd93d46f4ad492c6ddc51a2be
Autor:
Wahram Andrikyan, Lea Jung-Poppe, Anna Altenbuchner, Hagen Fabian Nicolaus, Barbara Pfistermeister, Harald Dormann, Martin F. Fromm, Renke Maas
Publikováno v:
Journal of Clinical Medicine, Vol 12, Iss 1, p 315 (2022)
Drug-related problems (DRPs), i.e., adverse drug reactions (ADRs) and medication errors (MEs), constitute a serious threat to the patient’s safety. DRPs are often insufficiently captured by clinical routine documentation, and thus, they frequently
Externí odkaz:
https://doaj.org/article/c79d125e7b864440ade1cf2c8ed341ea
Autor:
Pauline Dürr, Florian Meier, Katja Schlichtig, Anja Schramm, Lukas Schötz, Martin F. Fromm, Frank Dörje
Publikováno v:
Journal of Clinical Medicine, Vol 11, Iss 21, p 6392 (2022)
Drug-related problems (e.g., adverse drug reactions, ADR) are serious safety issues in patients treated with oral anticancer therapeutics (OAT). The previously published randomized AMBORA trial showed that an intensified clinical pharmacological/phar
Externí odkaz:
https://doaj.org/article/c4814ab8f84046d2a6fd8b0dd0ad2496
Autor:
Muhammad Erfan Uddin, Eric D. Eisenmann, Yang Li, Kevin M. Huang, Dominique A. Garrison, Zahra Talebi, Alice A. Gibson, Yan Jin, Mahesh Nepal, Ingrid M. Bonilla, Qiang Fu, Xinxin Sun, Alec Millar, Mikhail Tarasov, Christopher E. Jay, Xiaoming Cui, Heidi J. Einolf, Ryan M. Pelis, Sakima A. Smith, Przemysław B. Radwański, Douglas H. Sweet, Jörg König, Martin F. Fromm, Cynthia A. Carnes, Shuiying Hu, Alex Sparreboom
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 15, p 8607 (2022)
Dofetilide is a rapid delayed rectifier potassium current inhibitor widely used to prevent the recurrence of atrial fibrillation and flutter. The clinical use of this drug is associated with increases in QTc interval, which predispose patients to ven
Externí odkaz:
https://doaj.org/article/b8e2cb1b13fb4e639c3779666fe42092
Autor:
Katja Schlichtig, Lisa Cuba, Pauline Dürr, Laura Bellut, Norbert Meidenbauer, Frank Kunath, Peter J. Goebell, Andreas Mackensen, Frank Dörje, Martin F. Fromm, Bernd Wullich
Publikováno v:
Journal of Clinical Medicine, Vol 11, Iss 15, p 4558 (2022)
Oral antitumor therapeutics (OAT) bear a high risk for medication errors, e.g., due to drug–drug or drug–food interactions or incorrect drug intake. Advanced age, organ insufficiencies, and polymedication are putting uro-oncological patients at a
Externí odkaz:
https://doaj.org/article/43e00ea91ebc40d198e7b7c5e337aeea